+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Beta-Thalassemia Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5129097
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 166 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals
  • BlueBird Bio
  • Editas Medicine
  • Ionis Pharmaceuticals
  • Novartis
  • Protagonist Therapeutics
  • MORE
‘Beta-thalassemia Market Insights, Epidemiology, and Market Forecast - 2030' report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Beta-thalassemia in the United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom).

The Beta-thalassemia market report provides analysis regarding current treatment practices, emerging drugs like Zynteglo, PTG-300, ACE-011 market share of the individual therapies, and historical, current and forecasted RIE market size from 2017 to 2030, segmented by six major markets.

The report also covers current Beta-thalassemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030

Beta-thalassemia - Disease Understanding and Treatment Algorithm

Overview

Beta-thalassemia s (low beta-globin) are due to mutations in the HBB gene on chromosome 11, also inherited in an autosomal, recessive fashion. The severity of the disease depends on the nature of the mutation and on the presence of mutations in one or both alleles. A wide variety of different mutations (>200) have been documented that affect the Beta-globin gene, for which patients may be either homozygous or heterozygous. Phenotypic effects, therefore, range widely from slight impairment to the complete inhibition of Beta-globin chain synthesis.

Treatment

The thalassemia spectrum is clinically divided into two main categories based on the patient's need for blood transfusion, namely transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). The establishment of optimal transfusion programs and the application of aggressive iron chelation therapy (ICT) supported by advancements in magnetic resonance imaging (MRI) have led to an increase in the life expectancy of thalassemia patients.

This chapter covers the details of conventional and current medical therapies available for the treatment of Beta-thalassemia. It also provides the country-wise Beta-thalassemia treatment guidelines across the United States and Europe.

The Beta-thalassemia market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides RIE treatment algorithms and treatment guidelines in the US, and Europe.

Epidemiology

The Beta-thalassemia epidemiology chapters provide insights about historical and current Beta-thalassemia patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Beta-thalassemia epidemiology is segmented by the total prevalent cases of Beta-thalassemia minor, diagnosed prevalence of Beta-thalassemia, diagnosed Beta-thalassemia patients by disease type, complications associated with Beta-thalassemia patients. Besides, the report includes a thorough analysis of all segments.

Endocrine complications and Osteoporosis was found in the majority of patients with Beta-thalassemia

According to the publisher's, the total prevalent population of Beta-thalassemia in six major markets was 14,191 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Beta-thalassemia pipeline. It also helps to understand the Beta-thalassemia clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The clinical management of Beta-thalassemia generally involves blood transfusions, iron chelation, and treatments to alleviate symptoms of iron overload. Potentially curative treatments include bone marrow transplant in selected patients, and gene therapies that aim to partially, if not fully, correct the disorder. The gene therapy, lentiglobin (Zynteglo), which acts via the transplantation of lentiviral-transduced hematopoietic stem cells with increased production of Beta-globin, was approved for the treatment of TDT in the EU in 2019 but is yet to commercially treat its first patient in Germany.

Market Outlook:

The market size of Beta-thalassemia is expected to increase at a significant CAGR during the study period (2017-2030). Among all the six major markets, the United States accounted for the largest market size. Among EU5 countries, Italy had the largest market size, with USD 77.6 million in 2017, while Spain had the smallest market size of Beta-thalassemia with USD 2.2 million in 2017.

Drugs Uptake

This section focuses on the rate of uptake of the potential drugs in the Beta-thalassemia market or expected to get launched in the market during the study period 2017-2030. The analysis covers Beta-thalassemia market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Zynteglo (bluebirdbio) and Reblozyl (Acceleron/Celgene) are believed to be the most successful therapy amongst all the other expected drug candidates and shall account for the highest market revenue in the coming years.

Beta-thalassemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Beta-thalassemia.

Reimbursement Scenario in Beta-thalassemia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Beta-thalassemia domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Beta-thalassemia Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights
  • Expected launch of potential therapies will completely alter the market dynamics of Beta-thalassemia in the coming years. Iron chelating agents mainly rule market size of Beta-thalassemia. The upcoming therapies in each segment are estimated to change the market scenario
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Beta-thalassemia Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Beta-thalassemia Pipeline Analysis
  • Beta-thalassemia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Beta-thalassemia Report Key Strengths
  • 11-years Forecast
  • 6MM Coverage
  • Beta-thalassemia Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by therapies
  • Drugs Uptake
Beta-thalassemia Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the Beta-thalassemia market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Beta-thalassemia total market size as well as market size by therapies across the 6MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 6MM and which country will have the largest Beta-thalassemia market size during the forecast period (2017-2030)?
  • At what CAGR, the Beta-thalassemia market is expected to grow in 6MM during the forecast period (2017-2030)?
  • What would be the Beta-thalassemia market outlook across the 6MM during the forecast period (2017-2030)?
  • What would be the Beta-thalassemia market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden and unmet needs of Beta-thalassemia?
  • What is the historical Beta-thalassemia patient pool in six major markets covering the United States and EU5 (Germany, Spain, France, Italy, and the UK)?
  • What would be the forecasted patient pool of Beta-thalassemia in six major markets covering the United States and EU5 (Germany, Spain, France, Italy and the UK)?
  • What will be the growth opportunities in the 6MM concerning the patient population pertaining to Beta-thalassemia?
  • Out of all 6MM countries, which country would have the highest prevalent population of Beta-thalassemia during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 6MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Beta-thalassemia treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Beta-thalassemia in the USA and Europe?
  • What are the Beta-thalassemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Beta-thalassemia?
  • How many therapies are developed by each company for Beta-thalassemia?
  • How many are emerging therapies in mid-stage, and late stage of development for Beta-thalassemia treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Beta-thalassemia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Beta-thalassemia and their status?
  • What are the key designations that have been granted for the emerging therapies for Beta-thalassemia?
  • What is the global historical and forecasted market of Beta-thalassemia?
Reasons to buy:
  • The report will help in developing business strategies by understanding trends shaping and driving the Beta-thalassemia market
  • To understand the future market competition in the Beta-thalassemia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Beta-thalassemia in the US and Europe (Germany, Spain, Italy, France, and the United Kingdom)
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Beta-thalassemia market
  • To understand the future market competition in the Beta-thalassemia market
Which geography accounted for the largest Beta-thalassemia market size?

The United States accounted for the largest Beta-thalassemia market size.

What is forecasted Beta-thalassemia size in 2030?

estimates an increase in Beta-thalassemia Market Size during the study period, 2017-2030

What are the present Beta-thalassemia drivers?

Increasing disease prevalence, advances in genetics, More involvement of pharmaceutical in R&D

What are the Beta-thalassemia market barriers?

Global transfusion burden, continuity of care, Asymptomatic nature of disease

How many companies are developing drugs for Beta-thalassemia?

Currently, more than five companies are developing the drug for Beta-thalassemia

Which are the leading companies in Beta-thalassemia market?

Key Player - bluebird bio, Protagonist Therapeutics, Acceleron Pharma/Celgene Corporation, Agios Pharmaceuticals, Vifor Pharma and others

How is epidemiology segmented for Beta-thalassemia?

Total prevalent cases of Beta-thalassemia minor, the Diagnosed prevalence of Beta-thalassemia, Diagnosed Beta-thalassemia patients by disease type, Complications associated with Beta-thalassemia patients
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals
  • BlueBird Bio
  • Editas Medicine
  • Ionis Pharmaceuticals
  • Novartis
  • Protagonist Therapeutics
  • MORE
1 Key Insights

2 Executive Summary of Beta-thalassemia

3 SWOT Analysis for Beta-thalassemia

4 Beta-thalassemia Market Overview at a Glance
4.1 Market Share (%) Distribution of Beta-thalassemia in 2017
4.2 Market Share (%) Distribution of Beta-thalassemia in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Types
5.3 Molecular Genetics
5.4 Causes and Risk Factors
5.5 Complications associated with Beta-thalassemia
5.6 Etiology
5.7 Symptoms
5.8 Pathophysiology
5.9 Clinical Presentation of Beta-thalassemia
5.1 Diagnosis
5.11 Newborn Screening in Beta-thalassemia

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 6MM Total Prevalent Patient Population of Beta-thalassemia
6.3 Assumptions and Rationale – 6MM

7 Country Wise-Epidemiology of Beta-thalassemia
7.1 The United States
7.1.1 Total Prevalent Cases of Beta-thalassemia Minor in the United States
7.1.2 Diagnosed Prevalence of Beta-thalassemia in the United States
7.1.3 Diagnosed Beta-thalassemia Patients by Disease Type in the United States
7.1.4 Complications Associated with Beta-thalassemia Patients in The United States
7.2 EU5 Countries
7.2.1 Germany
7.2.1.1 Total Prevalent Cases of Beta-thalassemia Minor in Germany
7.2.1.2 Diagnosed Prevalence of Beta-thalassemia in Germany
7.2.1.3 Diagnosed Beta-thalassemia Patients by Disease Type in Germany
7.2.1.4 Complications Associated with Beta-thalassemia Patients in Germany
7.2.2 France
7.2.2.1 Total Prevalent Cases of Beta-thalassemia Minor in France
7.2.2.2 Diagnosed Prevalence of Beta-thalassemia in France
7.2.2.3 Diagnosed Beta-thalassemia Patients by Disease Type in France
7.2.2.4 Complications Associated with Beta-thalassemia Patients in France
7.2.3 Italy
7.2.3.1 Total Prevalent Cases of Beta-thalassemia Minor in Italy
7.2.3.2 Diagnosed Prevalence of Beta-thalassemia in Italy
7.2.3.3 Diagnosed Beta-thalassemia Patients by Disease Type in Italy
7.2.3.4 Complications Associated with Beta-thalassemia Patients in Italy
7.2.4 Spain
7.2.4.1 Total Prevalent Cases of Beta-thalassemia Minor in Spain
7.2.4.2 Diagnosed Prevalence of Beta-thalassemia in Spain
7.2.4.3 Diagnosed Beta-thalassemia Patients by Disease Type in Spain
7.2.4.4 Complications Associated with Beta-thalassemia Patients in Spain
7.2.5 The UK
7.2.5.1 Total Prevalent Cases of Beta-thalassemia Minor in the UK
7.2.5.2 Diagnosed Prevalence of Beta-thalassemia in the UK
7.2.5.3 Diagnosed Beta-thalassemia Patients by Disease Type in the UK
7.2.5.4 Complications associated with Beta-thalassemia Patients in the UK

8 Treatment and Management of Beta-thalassemia
8.1 Transfusion Therapy
8.2 Guidelines
8.3 Patient Journey
8.4 Organizations contributing towards Beta-thalassemia

9 Case Study
9.1 Acquired Beta-thalassemia as an Etiology of Microcytic Anemia in Primary Myelofibrosis
9.2 Beta-thalassemia Presenting as an Acute Neurological Complication: A Case Report

10 Unmet Needs

11 Marketed Products
11.1 Desferal: Novartis
11.1.1 Product Description
11.1.2 Regulatory Milestones
11.1.3 Generic Availability
11.2 Exjade: Novartis
11.2.1 Product Description
11.2.2 Regulatory Milestones
11.2.3 Generic Availability
11.2.4 Clinical Development
11.2.5 Safety and Efficacy
11.3 Ferrirpox (deferiprone): Apotex
11.3.1 Drug Description
11.3.2 Regulatory Milestones
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.4 ACE-536: Acceleron Pharma/Celgene Corporation
11.4.1 Product Description
11.4.2 Other Developmental Activities
11.4.3 Clinical Development
11.4.3.1 Clinical Trials Information
11.4.4 Safety and Efficacy

12 Emerging Therapies
12.1 LentiGlobin BB305: BlueBird Bio
12.1.1 Product Description
12.1.2 Other Development Activities
12.1.3 Clinical Development
12.1.3.1 Clinical Trials Information
12.1.4 Safety and Efficacy
12.1.5 Product Profile
12.2 PTG-300: Protagonist Therapeutics
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.3.1 Clinical Trials Information
12.2.4 Safety and Efficacy
12.3 ACE-011 (Sotatercept): Acceleron Pharma/Celgene Corporation
12.3.1 Product Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.3.1 Clinical Trials Information
12.3.4 Safety and Efficacy
12.4 Mitapivat: Agios Pharmaceuticals
12.4.1 Product Description
12.4.2 Clinical Development
12.4.2.1 Clinical Trials Information
12.4.3 Safety and Efficacy
12.5 IONIS TMPRSS6 LRx: Ionis Pharmaceuticals
12.5.1 Product Description
12.5.2 Clinical Development
12.5.2.1 Clinical Trials Information
12.5.3 Safety and Efficacy
12.6 VIT 2763: Vifor Pharma
12.6.1 Product Description
12.6.2 Other Developmental Activities
12.6.3 Clinical Development
12.6.3.1 Clinical Trials Information
12.6.4 Safety and Efficacy
12.7 Emeramide: EmeraMed
12.7.1 Product Description
12.7.2 Clinical Development
12.7.2.1 Clinical Trials Information

13 Other Promising Candidates
13.1 OTL-300: Orchard Therapeutics
13.1.1 Product Description
13.1.2 Other Developmental Activities
13.1.3 Clinical Development
13.1.3.1 Clinical Trials Information
13.1.4 Safety and Efficacy
13.2 ST-400: Sangamo Therapeutics/Sanofi
13.2.1 Product Description
13.2.2 Other Developmental Activities
13.2.3 Clinical Development
13.2.3.1 Clinical Trials Information
13.2.4 Safety and Efficacy
13.3 CTX001: CRISPR Therapeutics/Vertex Pharmaceuticals
13.3.1 Product Description
13.3.2 Other Developmental Activities
13.3.3 Clinical Development
13.3.3.1 Clinical Trials Information
13.3.4 Safety and Efficacy

14 Other Products in the News
14.1 DST-0509: DisperSol Technologies
14.1.1 Product Description
14.1.2 Other Developmental Activities
14.1.3 Clinical Development
14.1.3.1 Clinical Trials Information
14.1.4 Safety and Efficacy
14.2 ATIR201: Kiadis
14.2.1 Product Description
14.2.2 Clinical Development
14.3 Ruxolitinib: Incyte Corporation/Novartis
14.4 EDIT-301: Editas Medicine
14.5 Global Blood Therapeutics/Syros Pharmaceuticals

15 Discontinued Therapies
15.1 LJPC-401: La Jolla Pharmaceutical Company
15.1.1 Product Description
15.1.2 Other Developmental Activities
15.1.3 Clinical Development
15.1.3.1 Clinical Trials Information
15.1.4 Safety and Efficacy

16 Beta-thalassemia: Six Major Market Analysis
16.1 Key Findings
16.2 Market Size of Beta-thalassemia in 6MM

17 Market Outlook by Country
17.1 Assumptions and Rationale
17.2 The United States Market Size
17.2.1 Total Market size of Beta-thalassemia
17.2.2 Beta-thalassemia Market Size by Therapies
17.3 Germany Market Size
17.3.1 Total Market size of Beta-thalassemia
17.3.2 Beta-thalassemia Market Size by Therapies
17.4 France Market Size
17.4.1 Total Market size of Beta-thalassemia
17.4.2 Beta-thalassemia Market Size by Therapies
17.5 Italy Market Size
17.5.1 Total Market size of Beta-thalassemia
17.5.2 Beta-thalassemia Market Size by Therapies
17.6 Spain Market Size
17.6.1 Total Market size of Beta-thalassemia
17.6.2 Beta-thalassemia Market Size by Therapies
17.7 The UK Market Size
17.7.1 Total Market size of Beta-thalassemia
17.7.2 Beta-thalassemia Market Size by Therapies

18 Market Access and Reimbursement Landscape

19 Market Drivers

20 Market Barriers

21 Appendix
21.1 Report Methodology

22 Capabilities

23 Disclaimer

24 About the Publisher

List of Tables
Table 1: Summary of Beta-thalassemia Market, Epidemiology, and Key Events (2017–2030)
Table 2: Difference between Beta-thalassemia major and intermediate based on different parameters:
Table 3: Prevalent Patient Population of Beta-thalassemia in 6MM (2017–2030)
Table 4: Total Prevalent Cases Beta-thalassemia Minor in the United States (2017–2030)
Table 5: Diagnosed Prevalence of Beta-thalassemia in the United States (2017–2030)
Table 6: Diagnosed Beta-thalassemia Patients by Disease Type in the United States (2017–2030)
Table 7: Complications associated with Beta-thalassemia Patients in the United States (2017–2030)
Table 8: Total Prevalent Cases Beta-thalassemia Minor in Germany (2017–2030)
Table 9: Diagnosed Prevalence of Beta-thalassemia in Germany (2017–2030)
Table 10: Diagnosed Beta-thalassemia Patients by Disease Type in Germany (2017–2030)
Table 11: Complications associated with Beta-thalassemia Patients in Germany (2017–2030)
Table 12: Total Prevalent Cases Beta-thalassemia Minor in France (2017–2030)
Table 13: Diagnosed Prevalence of Beta-thalassemia in France (2017–2030)
Table 14: Diagnosed Beta-thalassemia Patients by Disease Type in France (2017–2030)
Table 15: Complications associated with Beta-thalassemia Patients in France (2017–2030)
Table 16: Total Prevalent Cases Beta-thalassemia Minor in Italy (2017–2030)
Table 17: Diagnosed Prevalence of Beta-thalassemia in Italy (2017–2030)
Table 18: Diagnosed Beta-thalassemia Patients by Disease Type in Italy (2017–2030)
Table 19: Complications associated with Beta-thalassemia Patients in Italy (2017–2030)
Table 20: Total Prevalent Cases Beta-thalassemia Minor in Spain (2017–2030)
Table 21: Diagnosed Prevalence of Beta-thalassemia in Spain (2017–2030)
Table 22: Diagnosed Beta-thalassemia Patients by Disease Type in Spain (2017–2030)
Table 23: Complications associated with Beta-thalassemia Patients in Spain (2017–2030)
Table 24: Total Prevalent Cases Beta-thalassemia Minor in the United Kingdom (2017–2030)
Table 25: Diagnosed Prevalence of Beta-thalassemia in the United Kingdom (2017–2030)
Table 26: Diagnosed Beta-thalassemia Patients by Disease Type in the United Kingdom (2017–2030)
Table 27: Complications associated with Beta-thalassemia Patients in the United Kingdom (2017–2030)
Table 29: Recommendations for transfusion therapy
Table 30: Recommendations for iron chelation therapy
Table 31: Organizations contributing toward Beta-thalassemia
Table 32: ACE-536, Clinical Trial Description 2020
Table 12.1: LentiGlobin BB305, Clinical Trial Description 2020
Table 34: PGT-300, Clinical Trial Description 2020
Table 35: ACE-011, Clinical Trial Description 2020
Table 36: AG-348, Clinical Trial Description 2020
Table 37: IONIS-TMPRSS6-LRx, Clinical Trial Description 2020
Table 38: VIT-2763, Clinical Trial Description 2020
Table 39: Emeramide, Clinical Trial Description 2020
Table 40: OTL-300, Clinical Trial Description 2020
Table 41: ST-400, Clinical Trial Description 2020
Table 42: OTL-300, Clinical Trial Description 2020
Table 43: DST-0509, Clinical Trial Description 2020
Table 44: LJPC-401, Clinical Trial Description 2020
Table 45: 6 Major Market Size of Beta-thalassemia in USD Million (2017–2030)
Table 46: The US Market size of Beta-thalassemia in USD Million (2017–2030)
Table 47: The US market size of Beta-thalassemia by Therapies in USD Million (2017–2030)
Table 48: Germany Market size of Beta-thalassemia in USD Million (2017–2030)
Table 49: Germany market size of Beta-thalassemia by Therapies in USD Million (2017–2030)
Table 50: France Market size of Beta-thalassemia in USD Million (2017–2030)
Table 51: France market size of Beta-thalassemia by Therapies in USD Million (2017–2030)
Table 52: Italy Market size of Beta-thalassemia in USD Million (2017–2030)
Table 53: Italy market size of Beta-thalassemia by Therapies in USD Million (2017–2030)
Table 54: Spain Market size of Beta-thalassemia in USD Million (2017–2030)
Table 55: Spain market size of Beta-thalassemia by Therapies in USD Million (2017–2030)
Table 56: The UK Market size of Beta-thalassemia in USD Million (2017–2030)
Table 57:The UK market size of Beta-thalassemia by Therapies in USD Million (2017–2030)

List of Figures
Figure 1: SWOT Analysis
Figure 2: Chromosome 11
Figure 3: Red blood cells: healthy and affected
Figure 4: Classification of Beta-thalassemia by types:
Figure 5: Inheritance pattern of Beta-thalassemia
Figure 6: Possible complications associated with Beta-thalassemia
Figure 7: Symptoms of Beta-thalassemia
Figure 8: Pathophysiology of Beta-thalassemia
Figure 9: Clinical and Psychosocial concerns among patient’s in different age-groups:
Figure 10: Diagnostic algorithm of Beta-thalassemia :
Figure 11: Prevalent Patient Population of Beta-thalassemia in 6MM (2017–2030)
Figure 12: Total Prevalent Cases of Beta-thalassemia Minor in the United States (2017–2030)
Figure 13: Diagnosed Prevalence of Beta-thalassemia in the United States (2017–2030)
Figure 14: Diagnosed Beta-thalassemia Patients by Disease Type in the United States (2017–2030)
Figure 15: Complications associated with Beta-thalassemia Patients in the United States (2017–2030)
Figure 16: Total Prevalent Cases of Beta-thalassemia Minor in Germany (2017–2030)
Figure 17: Diagnosed Prevalence of Beta-thalassemia in Germany (2017–2030)
Figure 18: Diagnosed Beta-thalassemia Patients by Disease Type in Germany (2017–2030)
Figure 19: Complications associated with Beta-thalassemia Patients in Germany (2017–2030)
Figure 20: Total Prevalent Cases of Beta-thalassemia Minor in France (2017–2030)
Figure 21: Diagnosed Prevalence of Beta-thalassemia in France (2017–2030)
Figure 22: Diagnosed Beta-thalassemia Patients by Disease Type in France (2017–2030)
Figure 23: Complications associated with Beta-thalassemia Patients in France (2017–2030)
Figure 24: Total Prevalent Cases of Beta-thalassemia Minor in Italy (2017–2030)
Figure 25: Diagnosed Prevalence of Beta-thalassemia in Italy (2017–2030)
Figure 26: Diagnosed Beta-thalassemia Patients by Disease Type in Italy (2017–2030)
Figure 27. Complications associated with Beta-thalassemia Patients in Italy (2017–2030)
Figure 28: Total Prevalent Cases of Beta-thalassemia Minor in Spain (2017–2030)
Figure 29: Diagnosed Prevalence of Beta-thalassemia in Spain (2017–2030)
Figure 30: Diagnosed Beta-thalassemia Patients by Disease Type in Spain (2017–2030)
Figure 31: Complications associated with Beta-thalassemia Patients in Spain (2017–2030)
Figure 32: Total Prevalent Cases of Beta-thalassemia Minor in the UK (2017–2030)
Figure 33: Diagnosed Prevalence of Beta-thalassemia in the UK (2017–2030)
Figure 34: Diagnosed Beta-thalassemia Patients by Disease Type in the UK (2017–2030)
Figure 35: Complications associated with Beta-thalassemia Patients in the UK (2017–2030)
Figure 37: Overview of current management of Beta-thalassemia
Figure 38: Beta-thalassemia and its severity based on transfusion dependency
Figure 39: Patient journey for Beta-thalassemia
Figure 40: Unmet Needs of Beta-thalassemia
Figure 41: Six Major Market Size of Beta-thalassemia in USD Million (2017–2030)
Figure 42: Market Size of Beta-thalassemia in the United States, USD Millions (2017–2030)
Figure 43: The US market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 44: Market Size of Beta-thalassemia in Germany, USD Millions (2017–2030)
Figure 45: Germany market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 46: Market Size of Beta-thalassemia in France, USD Millions (2017–2030)
Figure 47: France market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 48: Market Size of Beta-thalassemia in Italy, USD Millions (2017–2030)
Figure 49: Italy market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 50: Market Size of Beta-thalassemia in Spain, USD Millions (2017–2030)
Figure 51: Spain market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 52: Market Size of Beta-thalassemia in the UK, USD Millions (2017–2030)
Figure 53: The UK market size of Beta-thalassemia by therapies in USD Million (2017–2030)
Figure 54: Market Drivers for Beta-thalassemia
Figure 55: Market Barriers for Beta-thalassemia
Note: Product cover images may vary from those shown
3 of 3
  • Novartis
  • Apotex
  • Acceleron Pharma/Celgene Corporation
  • BlueBird Bio
  • Protagonist Therapeutics
  • Agios Pharmaceuticals
  • Ionis Pharmaceuticals
  • Vifor Pharma
  • EmeraMed
  • Orchard Therapeutics
  • Sangamo Therapeutics/Sanofi
  • CRISPR Therapeutics/Vertex Pharmaceuticals
  • DisperSol Technologies
  • Kiadis
  • Incyte Corporation/Novartis
  • Editas Medicine
  • La Jolla Pharmaceutical Company
Note: Product cover images may vary from those shown
Adroll
adroll